Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of iodinated contrast media-induced acute kidney injury
IRCT20170609034406N11Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of dapagliflozin in acute kidney failure (AKF) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Urine KIM-1 level, Plasma blood urea nitrogen and 3 more. Started Dec 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20170609034406N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170609034406N11.